Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xingshentongqiao decoction (XSTQ) is a traditional Chinese herbal medicine formulation investigated for the treatment of narcolepsy. Its therapeutic mechanism involves the modulation of hypocretin (orexin) signaling, specifically by upregulating the expression of orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R). Research indicates that XSTQ inhibits the proliferation and induces apoptosis of SH-SY5Y cells, effects associated with the repression of mitogen-activated protein kinase (MAPK) signaling pathways, including extracellular signal-regulated kinase (Erk) 1/2, p38 MAPK, and c-Jun N-terminal kinase (JNK). By modulating these pathways, XSTQ aims to restore hypocretin signaling balance, which is central to the pathogenesis of narcolepsy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xingshentongqiao decoction.